drugset / Trial / NCT02535416

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

NCT02535416

Phase 1 Completed 40 enrolled Arrowhead Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Single doses of ARC-520 will be evaluated at varying infusion rates and by slow bolus push.

Timeline

Start
2015-09
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ARC-520 Unknown 4 mg/kg Intravenous
Subject ARC-520 Unknown 5 mg/kg Intravenous
Subject ARC-520 Unknown 6 mg/kg Intravenous
Background Cetirizine Other / unclassified
Background Diphenhydramine Unknown

Indications

No indication recorded.